Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of Apta-1 in healthy volunteers with and without LPS challenge
NL-OMON51837Phase 1Completed
- Sponsor
- Aptahem
- Start
- Dec 2022
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis and septic shock comparing Apta-1 with Placebo (2 arms). Primary endpoints: Treatment-related adverse events and serious adverse events, Concomitant medication and 3 more. Started Dec 2022; status: completed.
02
Drugs
Apta-1
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NL-OMON51837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51837.